The EchoLution Viral RNA/DNA Kit is now available for the US diagnostic market and extracts nucleic acids from virus particles using a unique single centrifugation technology that reduces processing time for in vitro diagnostic analyses.

Quick and reliable clinical diagnostic tests are essential for detecting viral infections and providing appropriate medical care. The EchoLution Viral RNA/DNA Kit is specifically designed for extracting viral nucleic acids from a wide range of samples: It is particularly useful for the detection of respiratory viruses and enteropathogenic viruses in stool samples. The kit is IVDR compliant, CE marked, and FDA listed, making it an ideal solution for diagnostic laboratory routines that require high-quality standards. With a more sustainable composition, it offers the same performance as the previously available EchoLution Viral RNA/DNA Swab Kit Plus. This predecessor kit was used extensively for PCR diagnostics in Europe during the SARS-CoV-2 pandemic with more than 12 million tests carried out.

“BioEcho is proud to offer a product that enables convenient extraction of viral RNA and DNA. We are convinced that these products, which are FDA-listed in the USA, will significantly improve the efficiency of diagnostic laboratories and ultimately reduce response times for patients,” said Lydia Willing, general manager at BioEcho Life Sciences Inc.

One of the main advantages of the EchoLution Viral RNA/DNA kit is its technology, which is based on tailor-made lysis followed by nucleic acid purification in a single centrifugation step. No incubation is required for respiratory viruses, and only 10 minutes for stool samples. This means that the purified viral RNA or DNA from 96 samples is ready for use within 20-30 minutes, depending on the sample type (medium swabs, dry swabs or stool samples). The kit is available in various formats (48 and 96-well plates) to adapt laboratory throughput to requirements. The product is compatible with a wide range of downstream applications, such as qPCR.

About BioEchoLife Sciences GmbH

BioEcho LifeSciences is a specialized solution provider for nucleic acid extraction and analysis. We develop disruptive technologies, products and workflows that make the processing of nucleic acids significantly easier and faster, significantly increase throughput and deliver reliable results. Our EchoLution™ technology enables the fastest DNA and RNA extraction currently available on the market in just one step and drastically reduces the associated plastic waste.

BioEcho was founded in 2016 by leading industry experts. The company is headquartered in Cologne, which is certified according to ISO 9001 and ISO 13485.

‍

BioEcho. The Nucleic Acid Experts.

www.bioecho.de

‍

The EchoLution Viral RNA/DNA Kit is now available for the US diagnostic market and extracts nucleic acids from virus particles using a unique single centrifugation technology that reduces processing time for in vitro diagnostic analyses.

Quick and reliable clinical diagnostic tests are essential for detecting viral infections and providing appropriate medical care. The EchoLution Viral RNA/DNA Kit is specifically designed for extracting viral nucleic acids from a wide range of samples: It is particularly useful for the detection of respiratory viruses and enteropathogenic viruses in stool samples. The kit is IVDR compliant, CE marked, and FDA listed, making it an ideal solution for diagnostic laboratory routines that require high-quality standards. With a more sustainable composition, it offers the same performance as the previously available EchoLution Viral RNA/DNA Swab Kit Plus. This predecessor kit was used extensively for PCR diagnostics in Europe during the SARS-CoV-2 pandemic with more than 12 million tests carried out.

“BioEcho is proud to offer a product that enables convenient extraction of viral RNA and DNA. We are convinced that these products, which are FDA-listed in the USA, will significantly improve the efficiency of diagnostic laboratories and ultimately reduce response times for patients,” said Lydia Willing, general manager at BioEcho Life Sciences Inc.

One of the main advantages of the EchoLution Viral RNA/DNA kit is its technology, which is based on tailor-made lysis followed by nucleic acid purification in a single centrifugation step. No incubation is required for respiratory viruses, and only 10 minutes for stool samples. This means that the purified viral RNA or DNA from 96 samples is ready for use within 20-30 minutes, depending on the sample type (medium swabs, dry swabs or stool samples). The kit is available in various formats (48 and 96-well plates) to adapt laboratory throughput to requirements. The product is compatible with a wide range of downstream applications, such as qPCR.

About BioEchoLife Sciences GmbH

BioEcho LifeSciences is a specialized solution provider for nucleic acid extraction and analysis. We develop disruptive technologies, products and workflows that make the processing of nucleic acids significantly easier and faster, significantly increase throughput and deliver reliable results. Our EchoLution™ technology enables the fastest DNA and RNA extraction currently available on the market in just one step and drastically reduces the associated plastic waste.

BioEcho was founded in 2016 by leading industry experts. The company is headquartered in Cologne, which is certified according to ISO 9001 and ISO 13485.

‍

BioEcho. The Nucleic Acid Experts.

www.bioecho.de

‍